Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio sulla tollerabilità, sicurezza ed efficacia di asciminib in pazienti con leucemia mieloide cronica positiva per il cromosoma Philadelphia in fase cronica in Germania (ASC2ADHERE)

5 novembre 2026 aggiornato da: Novartis Pharmaceuticals

Uno studio non interventistico sulla tollerabilità, sicurezza ed efficacia di Asciminib in pazienti con leucemia mieloide cronica con cromosoma Philadelphia positivo in fase cronica, di nuova diagnosi o pretrattati in Germania - lo studio ASC2ADHERE

The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).

Panoramica dello studio

Stato

Reclutamento

Tipo di studio

Osservativo

Iscrizione (Stimato)

380

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Novartis Pharmaceuticals

Luoghi di studio

      • Amberg, Germania, 92224
        • Reclutamento
        • Novartis Investigative Site
      • Bad Friedrichshall, Germania, 74177
        • Reclutamento
        • Novartis Investigative Site
      • Bad Liebenwerda, Germania, 04924
        • Reclutamento
        • Novartis Investigative Site
      • Bad Saarow, Germania, 15526
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 10437
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 10365
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 12552
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 10559
        • Reclutamento
        • Novartis Investigative Site
      • Berlin, Germania, 12487
        • Reclutamento
        • Novartis Investigative Site
      • Bremerhaven, Germania, 27568
        • Reclutamento
        • Novartis Investigative Site
      • Buchholz Nordheide, Germania, 21244
        • Reclutamento
        • Novartis Investigative Site
      • Cottbus, Germania, 03046
        • Reclutamento
        • Novartis Investigative Site
      • Deggendorf, Germania, 94469
        • Reclutamento
        • Novartis Investigative Site
      • Detmold, Germania, 32756
        • Reclutamento
        • Novartis Investigative Site
      • Dorfen, Germania, 84405
        • Reclutamento
        • Novartis Investigative Site
      • Dortmund, Germania, 44263
        • Reclutamento
        • Novartis Investigative Site
      • Dresden, Germania, 01307
        • Reclutamento
        • Novartis Investigative Site
      • Dresden, Germania, 01127
        • Reclutamento
        • Novartis Investigative Site
      • Düren, Germania, 52353
        • Reclutamento
        • Novartis Investigative Site
      • Erfurt, Germania, 99085
        • Reclutamento
        • Novartis Investigative Site
      • Erfurt, Germania, 99084
        • Reclutamento
        • Novartis Investigative Site
      • Eschweiler, Germania, 52249
        • Reclutamento
        • Novartis Investigative Site
      • Göttingen, Germania, 37073
        • Reclutamento
        • Novartis Investigative Site
      • Hanover, Germania, 30161
        • Reclutamento
        • Novartis Investigative Site
      • Hanover, Germania, 30625
        • Reclutamento
        • Novartis Investigative Site
      • Hildesheim, Germania, 31135
        • Reclutamento
        • Novartis Investigative Site
      • Kiel, Germania, 24105
        • Reclutamento
        • Novartis Investigative Site
      • Leipzig, Germania, 04103
        • Reclutamento
        • Novartis Investigative Site
      • Leverkusen, Germania, 51375
        • Reclutamento
        • Novartis Investigative Site
      • Mutlangen, Germania, 73557
        • Reclutamento
        • Novartis Investigative Site
      • Naunhof, Germania, 04683
        • Reclutamento
        • Novartis Investigative Site
      • Neuss, Germania, 41462
        • Reclutamento
        • Novartis Investigative Site
      • Offenburg, Germania, 77654
        • Reclutamento
        • Novartis Investigative Site
      • Oldenburg, Germania, 26121
        • Reclutamento
        • Novartis Investigative Site
      • Parchim, Germania, 19370
        • Reclutamento
        • Novartis Investigative Site
      • Potsdam, Germania, 14467
        • Reclutamento
        • Novartis Investigative Site
      • Potsdam, Germania, 14482
        • Reclutamento
        • Novartis Investigative Site
      • Schorndorf, Germania, 73614
        • Reclutamento
        • Novartis Investigative Site
      • Schwetzingen, Germania, 68723
        • Reclutamento
        • Novartis Investigative Site
      • Soest, Germania, 59494
        • Reclutamento
        • Novartis Investigative Site
      • Stade, Germania, 21680
        • Reclutamento
        • Novartis Investigative Site
      • Torgau, Germania, 04860
        • Reclutamento
        • Novartis Investigative Site
      • Ulm, Germania, 89081
        • Reclutamento
        • Novartis Investigative Site
      • Wetzlar, Germania, 35578
        • Reclutamento
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Baden-Baden, Baden-Wurttemberg, Germania, 76532
        • Reclutamento
        • Novartis Investigative Site
      • Heidenheim, Baden-Wurttemberg, Germania, 89522
        • Reclutamento
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Germania, 74523
        • Reclutamento
        • Novartis Investigative Site
      • Winnenden, Baden-Wurttemberg, Germania, 71364
        • Reclutamento
        • Novartis Investigative Site
    • Bavaria
      • Aschaffenburg, Bavaria, Germania, 63739
        • Reclutamento
        • Novartis Investigative Site
      • Augsburg, Bavaria, Germania, 86152
        • Reclutamento
        • Novartis Investigative Site
      • Donauwörth, Bavaria, Germania, 86609
        • Reclutamento
        • Novartis Investigative Site
      • Herrsching am Ammersee, Bavaria, Germania, 82211
        • Reclutamento
        • Novartis Investigative Site
      • Kempten (Allgäu), Bavaria, Germania, 87439
        • Reclutamento
        • Novartis Investigative Site
      • Landsberg am Lech, Bavaria, Germania, 86899
        • Reclutamento
        • Novartis Investigative Site
      • Munich, Bavaria, Germania, 81241
        • Reclutamento
        • Novartis Investigative Site
      • Munich, Bavaria, Germania, 81377
        • Reclutamento
        • Novartis Investigative Site
      • Regensburg, Bavaria, Germania, 93053
        • Reclutamento
        • Novartis Investigative Site
    • Free Hanseatic City of Bremen
      • Bremerhaven, Free Hanseatic City of Bremen, Germania, 27576
        • Reclutamento
        • Novartis Investigative Site
    • Hesse
      • Kassel, Hesse, Germania, 34125
        • Reclutamento
        • Novartis Investigative Site
      • Offenbach, Hesse, Germania, 63065
        • Reclutamento
        • Novartis Investigative Site
    • Lower Saxony
      • Goslar, Lower Saxony, Germania, 38642
        • Reclutamento
        • Novartis Investigative Site
      • Rotenburg (Wümme), Lower Saxony, Germania, 27356
        • Reclutamento
        • Novartis Investigative Site
      • Twistringen, Lower Saxony, Germania, 27239
        • Reclutamento
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Germania, 50674
        • Reclutamento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Germania, 50677
        • Reclutamento
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Germania, 51103
        • Reclutamento
        • Novartis Investigative Site
      • Solingen, North Rhine-Westphalia, Germania, 42653
        • Reclutamento
        • Novartis Investigative Site
      • Wesel, North Rhine-Westphalia, Germania, 46483
        • Reclutamento
        • Novartis Investigative Site
    • Saxony
      • Zittau, Saxony, Germania, 02763
        • Reclutamento
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Halle, Saxony-Anhalt, Germania, 06110
        • Reclutamento
        • Novartis Investigative Site
      • Merseburg, Saxony-Anhalt, Germania, 06217
        • Reclutamento
        • Novartis Investigative Site
    • Schleswig-Holstein
      • Oldenburg in Holstein, Schleswig-Holstein, Germania, 23758
        • Reclutamento
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Germania, 04600
        • Reclutamento
        • Novartis Investigative Site
      • Saalfeld, Thuringia, Germania, 07318
        • Reclutamento
        • Novartis Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 100 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Adult Ph+ CML-CP patients, either newly diagnosed or previously treated with one ATP-competitive TKI, who initiate TKI treatment as recommended by the treating physician in a hematology center in Germany.

Descrizione

Inclusion criteria:

  1. Written informed consent must be obtained before participation in the study/prior to any study-related documentation.
  2. Adult patients (≥18 years of age) with a confirmed diagnosis of Ph+ CML-CP. The presence of the Philadelphia chromosome may alternatively be confirmed by molecular detection of a BCR::ABL1 fusion gene/transcript (e.g., by reverse transcription polymerase chain reaction (RT-PCR)), in accordance with the World Health Organization (WHO) 2022 classification.
  3. Patients who are either newly diagnosed or have received treatment with exactly one prior TKI. Prior TKI treatment is only permitted for patients in the Asciminib Cohort. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be newly diagnosed and must not have received any prior TKI treatment.
  4. Patients for whom the treating physician has made a clinical decision to initiate treatment with asciminib or another TKI (imatinib, dasatinib, bosutinib, nilotinib) as part of routine care. The clinical decision for treatment must have been made prior to enrollment. Treatment must not have started more than 14 days before study inclusion, and treatment may also begin after baseline assessment.
  5. Patients willing to participate in routine follow-up visits and complete patient-reported outcome questionnaires over the course of the study.

Exclusion criteria:

  1. Patients with contraindications to their respective chronic myeloid leukemia (CML) treatment as per the applicable Summary of Product Characteristics (SmPC) and relevant national treatment guidelines (e.g. Onkopedia CML), as well as additional disease- or treatment-related characteristics associated with distinct clinical scenarios that differ from the intended study population, including situations with specific treatment requirements or limited comparability, in which reliable interpretation of study outcomes may not be feasible, including the following asciminib specific considerations:

    • In first- or second-line treatment: presence of BCR::ABL1 fusion transcripts lacking exon a2 (e.g. e13a3, e14a3, e1a3).

    • In second-line treatment:

      • known BCR::ABL1 mutations associated with partial or complete resistance to asciminib (e.g. M244V, F359I/V/C).
      • presence of the BCR::ABL1 T315I mutation, regardless of eligibility for treatment according to SmPC (e.g., specific indication and dosing regimens).
  2. Patients receiving or planned to receive asciminib or other TKIs outside the approved label (off-label use), including use in unapproved dosing regimens or frequency not covered by the respective SmPC.

  3. Patients currently participating in an interventional clinical trial.

  4. Patients unable or unwilling to provide written informed consent.

  5. Patients who are unable to reliably complete patient-reported outcome questionnaires due to cognitive or language limitations relevant to the study assessments.

  6. Patients for whom long-term follow-up is not feasible due to expected relocation or other logistical constraints.

  7. The restriction to a maximum of one prior ATP-competitive TKI applies exclusively to patients treated with asciminib. Patients in the comparator cohorts (imatinib, dasatinib, bosutinib, nilotinib) must be TKI-naïve and are included at the start of their first-line TKI therapy and are not eligible if they have received any prior TKI treatment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Asciminib Cohort

Adult patients with Ph+ CML-CP, either newly diagnosed or previously treated with one TKI, who are treated with asciminib.

Imatinib Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with imatinib who have not received any prior TKI treatment.

Second-generation TKI Cohort

Adult patients newly diagnosed with Ph+ CML-CP treated with dasatinib, bosutinib, or nilotinib who have not received any prior TKI treatment.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Patients With Major Molecular Response (MMR) at 12 Months
Lasso di tempo: Month 12

MMR is defined as a BCR::ABL1 level ≤ 0.1% according to the International Scale (IS).

Month 12

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentuale di pazienti per motivo della decisione terapeutica con TKI documentata dal medico curante
Lasso di tempo: Valore basale
Valore basale
Percentuale di pazienti con riduzione della dose per motivo della riduzione della dose
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Percentage of Patients With Treatment Interruption by Reason for Interruption
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Percentuale di pazienti che hanno interrotto il trattamento per motivo di interruzione
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Tempo alla Sospensione del Trattamento
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Tempo all'Interruzione del Trattamento
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Time to Dose Reduction
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Tempo alla Sospensione del Trattamento a Causa di Eventi Avversi (TTSA)
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21 e 24 mesi
3, 6, 9, 12, 15, 18, 21 e 24 mesi
Percentage of Patients by Clinical Characteristic
Lasso di tempo: Baseline

Characteristics include, but are not limited to, detection of Philadelphia chromosome or BCR::ABL1 transcript, prior treatment, and Eastern Cooperative Oncology Group (ECOG) performance status.

Baseline
Percentage of Patients With Early Molecular Response (EMR) at 3 Months
Lasso di tempo: Month 3

EMR is defined as BCR::ABL1 ≤10% IS.

Month 3
Percentage of Patients With Molecular Response 2 (MR2)
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

MR2 is defined as BCR::ABL1 ≤1% IS.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With MMR
Lasso di tempo: 3, 6, 9, 15, 18, 21, and 24 months

MMR is defined as BCR::ABL1 ≤0.1% IS.

3, 6, 9, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.0
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.0): ≤0.01% BCR::ABL1 IS and Reference gene copies >10,000 ABL1 or >24,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR4.5
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR4.5): ≤0.0032% BCR::ABL1 IS and Reference gene copies >32,000 ABL1 or >77,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Percentage of Patients With Deep Molecular Response: MR5
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

Deep Molecular Response (MR5): ≤0.001% BCR::ABL1 IS and Reference gene copies >100,000 ABL1 or >240,000 GUSB.

3, 6, 9, 12, 15, 18, 21, and 24 months
Medication Adherence Report Scale (MARS-5) Score
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The MARS-5 questionnaire is a validated self-report questionnaire developed to assess patient adherence to prescribed medication, focusing on both intentional and unintentional non-adherence. It consists of 5 items, each rated on a 5-point Likert Scale from 0 (always) to 5 (never). The total score ranges from 5 to 25, with higher scores indicating better adherence to treatment.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-C30 contains 30 questions answered by the patient. There are 9 multiple-item scales: 5 scales that assess aspects of functioning (physical, role functioning, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health status/Quality of Life (QOL) scale. There are 5 single-item measures assessing additional symptoms (i.e., dyspnea, loss of appetite, insomnia, constipation, and diarrhea) and a single item concerning perceived financial impact of the disease. All but 2 questions have 4-point scales ranging from "Not at all" to "Very much." The 2 questions concerning global health status/QOL have 7-point scales with ratings ranging from "Very poor" to "Excellent." For each of the 14 domains, final scores are transformed such that they range from 0-100, where higher scores indicate improvement.

3, 6, 9, 12, 15, 18, 21, and 24 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for CML (EORTC QLQ-CML24) Score
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The EORTC QLQ-CML24 was designed to supplement the QLQ-C30 - the QLQ-CML24 is not a stand-alone instrument but is to be used in conjunction with the QLQ-C30.

The EORTC QLQ-CML24 is composed of 4 multi-item scales and 2 single-item scales. The module consists of 24 items assessing symptom burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items are measured on 4 levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores are averaged and transformed to 0 to 100.

A higher score in symptom burden, impact on worry/mood, impact on daily life, and body image problems domains indicates a worse outcome. A higher score in satisfaction with social life and satisfaction with care and information domains indicates a higher level of satisfaction.

3, 6, 9, 12, 15, 18, 21, and 24 months
Work Productivity and Activity Impairment - General Health (WPAI-GH) Score
Lasso di tempo: 3, 6, 9, 12, 15, 18, 21, and 24 months

The WPAI-GH is a patient-reported 6 item questionnaire which addresses absenteeism, presenteeism, overall work productivity loss, and activity impairment for the 7 days prior to the assessment. Work productivity and activity impairment outcomes are presented as impairment percentages ranging from 0 to 100 with a higher percentage indicating greater impairment and less productivity.

3, 6, 9, 12, 15, 18, 21, and 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 aprile 2026

Completamento primario (Stimato)

30 settembre 2030

Completamento dello studio (Stimato)

30 settembre 2030

Date di iscrizione allo studio

Primo inviato

16 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

16 aprile 2026

Primo Inserito (Effettivo)

24 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi